Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) announced on December 1, 2025 that its Compensation Committee approved inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to two newly hired non-executive employees.
On November 30, 2025 the committee granted restricted stock awards covering, in the aggregate, up to 45,685 restricted shares of Abeona common stock. The awards vest one-third on each anniversary of the grant date, so each grantee’s awards become fully vested on the third anniversary, subject to continued employment.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ABEO declined 5.72%, reflecting a notable negative market reaction. This price movement removed approximately $16M from the company's valuation, bringing the market cap to $259M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Gene‑therapy and biotech peers showed mixed moves, with names like AUTL up 3.25% and RCKT and TECX down 4.96% and 3.04%, suggesting stock‑specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Commercial treatment news | Positive | +5.3% | First commercial ZEVASKYN treatment for RDEB patients was announced. |
| Dec 01 | Inducement equity grants | Negative | -5.7% | Inducement restricted stock awards to new hires under Nasdaq Rule 5635(c)(4). |
| Nov 12 | Q3 results, updates | Positive | +18.5% | Q3 2025 results with strong cash position and early ZEVASKYN momentum. |
| Nov 07 | Earnings date, conference | Neutral | +0.2% | Scheduled Q3 call and participation in Stifel 2025 Healthcare Conference. |
| Nov 03 | Inducement equity grants | Negative | -0.6% | Inducement restricted stock awards to eleven new hires under Nasdaq Rule 5635(c)(4). |
Across the last five announcements, including prior inducement grants, price moves generally aligned with the perceived tone: positive clinical and financial updates saw gains, while inducement grant disclosures coincided with modest declines.
Over the past months, Abeona highlighted several milestones, including Q3 2025 financial results on Nov 12, 2025 with strengthened liquidity and commercialization build‑out, and the first commercial ZEVASKYN treatment on Dec 8, 2025. Administrative updates such as earnings call scheduling and repeated inducement equity grants under Nasdaq Listing Rule 5635(c)(4) showed smaller stock reactions. The current inducement grants continue this pattern of routine hiring‑related equity awards alongside an active launch phase for ZEVASKYN.
Market Pulse Summary
The stock moved -5.7% in the session following this news. A negative reaction despite the routine nature of this filing would fit prior patterns where inducement grants under Nasdaq Rule 5635(c)(4) coincided with modest declines. The grants cover only 45,685 restricted shares to two employees, but investors may still focus on incremental dilution amid high short interest of 16.67% and recent insider net selling totaling 64,300 shares. Historical behavior suggests headlines tied to compensation have not been strong upside catalysts.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock financial
AI-generated analysis. Not financial advice.
CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On November 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 45,685 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com
FAQ
What did Abeona Therapeutics announce on December 1, 2025 regarding ABEO stock?
When were the Abeona ABEO restricted stock grants approved and granted?
How do the Abeona ABEO restricted shares vest for the new hires?
Why did Abeona grant these ABEO shares under Nasdaq Rule 5635(c)(4)?
How many employees received inducement grants from Abeona (ABEO)?
